Janssen Pharmaceutica NV
Also known as: Jannsen Pharmaceutica | Janssen Asia-Pacific Medical Affairs | Janssen Biologics BV | Janssen Biologics B.V. | Janssen Biotech, Inc. | Janssen-Cilag A.G., Switzerland | Janssen Cilag N.V./S.A. | Janssen Cilag Pharmaceutica S.A.C.I., Greece | Janssen Cilag S.A.S. | Janssen Diagnostics, LLC | Janssen, GlaxoSmithKline (GSK) | Janssen Inc. | Janssen Infectious Diseases BVBA | Janssen Korea Ltd. | Janssen Korea, Ltd | Janssen Korea, Ltd. | Janssen Korea, Ltd., Korea | Janssen, LP | Janssen, L.P. - Investigator Initiated Studies Program | Janssen Medical Affairs | Janssen-Ortho Inc., Canada | Janssen-Ortho LLC | Janssen Pharmaceutica | Janssen Pharmaceutical Companies of Johnson & Johnson | Janssen Pharmaceutical K.K. | Janssen Pharmaceuticals | Janssen Pharmaceuticals Inc | Janssen Pharmaceutica NV | Janssen Pharmaceutica N.V. | Janssen Pharmaceutica N.V., Belgium | Janssen Pharmaceutica, Philippines | JANSSEN PHARMS | Janssen R&D Ireland | Janssen R&D, L.L.C. | Janssen Research & Development | Janssen Research & Development L.L.C | Janssen Research & Development, LLC | Janssen Research & Development, L.L.C | Janssen Research & Development, L.L.C. | Janssen Sciences Ireland UC | Janssen Scientific Affairs, LLC | Janssen Services, LLC | Janssen Services, L.L.C. | Janssen Vaccines & Prevention B.V.
Highest phase reached
Phase 4
First clinical trial
Apr 1, 1995First marketed drug
Aug 15, 1958First NDA
Aug 15, 1958Last known activity
Dec 31, 2025
Timeline
1950s
- Jan 1, 1953
Janssen Pharmaceutica NV— Founded
- Aug 15, 1958
chlorzoxazone— NDA Organization
1960s
- Jan 1, 1961
Johnson and Johnson— Acquired By
2010s
- Mar 19, 2015
XO1— Acquired
2020s
- Mar 18, 2021
ponesimod— Marketing Organization
Drugs by trial phase (391 distinct, 959 trials)
Phase 4 (72 own, 0 via acquisition)
Phase 3 (87 own, 0 via acquisition)
Phase 2 (134 own, 0 via acquisition)
Phase 1 (97 own, 0 via acquisition)
Other trials (1 own, 0 via acquisition)
Indications
Approved for
Studied for
- Acne Vulgaris
- Acquired Immunodeficiency Syndrome
- Acute Disease
- Adenocarcinoma
- Adenocarcinoma of Lung
- Aggression
- Alcoholism
- Alzheimer Disease
- Amyloidosis
- Anemia
- Anemia, Neonatal
- Anemia, Sickle Cell
- Anorexia
- Anorexia Nervosa
- Anxiety Disorders
- Arteritis
- Arthritis
- Arthritis, Psoriatic
- Arthritis, Rheumatoid
- Asperger Syndrome
- Aspergillosis
- Asthma
- Astrocytoma
- Atrial Fibrillation
- Attention Deficit and Disruptive Behavior Disorders
- Attention Deficit Disorder with Hyperactivity
- Autism Spectrum Disorder
- Autistic Disorder
- Autoimmune Diseases
- Back Pain
- Behcet Syndrome
- Bipolar Disorder
- Blastomycosis
- Borderline Personality Disorder
- Brain Diseases
- Breakthrough Pain
- Breast Neoplasms
- Cancer Pain
- Candidiasis
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Cardiovascular Diseases
- Central Nervous System Diseases
- Chronic Pain
- Cocaine-Related Disorders
- Cognition Disorders
- Cognitive Dysfunction
- Coinfection
- Colitis
- Colitis, Ulcerative
- Colonic Diseases
- Colorectal Neoplasms
- Communicable Diseases
- Complex Regional Pain Syndromes
- Compulsive Personality Disorder
- Conduct Disorder
- Coronary Artery Disease
- Coronary Disease
- Coronavirus Infections
- Critical Illness
- Crohn Disease
- Crush Injuries
- Cryptococcosis
- Cryptosporidiosis
- Cytomegalovirus Infections
- Delusions
- Dementia
- Dementia, Vascular
- Dengue
- Depression
- Depressive Disorder
- Depressive Disorder, Treatment-Resistant
- Dermatitis
- Dermatitis, Atopic
- Dermatomyositis
- Developmental Disabilities
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2
- Diabetic Neuropathies
- Diarrhea
- Disease
- Disease Progression
- Ear Diseases
- Eczema
- Embolism
- Emergencies
- Epilepsy
- Epilepsy, Rolandic
- Epstein-Barr Virus Infections
- Esophagitis
- Esophagitis, Peptic
- Febrile Neutropenia
- Fibrosis
- Frailty
- Gastroesophageal Reflux
- Gastroparesis
- Giant Cell Arteritis
Marketed drugs (6)
Subsidiaries (1 direct, 1 total across the full acquisition tree)
Recent trials (50)
- NCT05161598Study directorN/A—
- NCT05161598Lead sponsorN/A—
- NCT03847376Study directorN/A—
- NCT03847376Lead sponsorN/A—
- NCT04264884Lead sponsorN/A—
- NCT04264884Study directorN/A—
- NCT04452994Lead sponsorN/A—
- NCT04817657Study directorN/A—
- NCT04817657Lead sponsorN/A—
- NCT04948398Study directorN/A—
- NCT04948398Lead sponsorN/A—
- NCT03825484Lead sponsorN/A—
- NCT03825484Study directorN/A—
- NCT05346835Lead sponsorN/A—
- NCT04599712Lead sponsorN/A—
Details
- Founded
- Beerse, BE Jan 1, 1953
- First NDA
- Aug 15, 1958
- Last known activity
- Dec 31, 2025
Designations held
- Orphan drug
- Fast track
- Priority review
- Breakthrough therapy
- Accelerated approval